Insider Selling: ANI Pharmaceuticals (NASDAQ:ANIP) VP Sells 500 Shares of Stock

ANI Pharmaceuticals, Inc. (NASDAQ:ANIP) VP Meredith Cook sold 500 shares of the business’s stock in a transaction dated Friday, June 12th. The stock was sold at an average price of $82.03, for a total transaction of $41,015.00. Following the transaction, the vice president owned 77,890 shares in the company, valued at $6,389,316.70. This represents a 0.64% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Meredith Cook also recently made the following trade(s):

• On Wednesday, May 13th, Meredith Cook sold 500 shares of ANI Pharmaceuticals stock. The shares were sold at an average price of $78.16, for a total transaction of $39,080.00.
• On Monday, April 13th, Meredith Cook sold 500 shares of ANI Pharmaceuticals stock. The shares were sold at an average price of $77.95, for a total transaction of $38,975.00.

ANI Pharmaceuticals Stock Performance

ANI Pharmaceuticals stock traded up $0.61 during midday trading on Monday, reaching $82.29. 293,873 shares of the company’s stock were exchanged, compared to its average volume of 393,012. The stock’s 50-day simple moving average is $79.72 and its 200 day simple moving average is $79.41. The firm has a market cap of $1.87 billion, a price-to-earnings ratio of 20.83 and a beta of 0.44. The company has a debt-to-equity ratio of 1.06, a quick ratio of 2.52 and a current ratio of 3.12. ANI Pharmaceuticals, Inc. has a 52 week low of $62.14 and a 52 week high of $99.50.

ANI Pharmaceuticals (NASDAQ:ANIP) last released its quarterly earnings data on Friday, May 8th. The specialty pharmaceutical company reported $2.05 earnings per share (EPS) for the quarter, beating the consensus estimate of $1.28 by $0.77. ANI Pharmaceuticals had a return on equity of 27.51% and a net margin of 9.98%.The firm had revenue of $237.46 million for the quarter, compared to analyst estimates of $207.63 million. During the same quarter in the prior year, the company earned $1.70 earnings per share. The business’s revenue for the quarter was up 20.5% compared to the same quarter last year. ANI Pharmaceuticals has set its FY 2026 guidance at 9.190-9.690 EPS. On average, analysts expect that ANI Pharmaceuticals, Inc. will post 8.07 earnings per share for the current fiscal year.

Institutional Trading of ANI Pharmaceuticals

Several hedge funds have recently added to or reduced their stakes in ANIP. Advisors Asset Management Inc. acquired a new position in ANI Pharmaceuticals in the 1st quarter valued at $28,000. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. boosted its position in shares of ANI Pharmaceuticals by 4.5% in the first quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 10,993 shares of the specialty pharmaceutical company’s stock valued at $736,000 after acquiring an additional 470 shares during the period. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC grew its stake in shares of ANI Pharmaceuticals by 0.9% in the first quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 48,322 shares of the specialty pharmaceutical company’s stock valued at $3,235,000 after acquiring an additional 423 shares in the last quarter. Jane Street Group LLC acquired a new position in shares of ANI Pharmaceuticals in the first quarter valued at about $2,706,000. Finally, Norges Bank bought a new position in ANI Pharmaceuticals during the second quarter worth about $625,000. 76.05% of the stock is owned by institutional investors and hedge funds.

Analyst Upgrades and Downgrades

ANIP has been the subject of a number of research analyst reports. Wall Street Zen raised shares of ANI Pharmaceuticals from a “buy” rating to a “strong-buy” rating in a research report on Saturday, May 9th. Weiss Ratings reissued a “hold (c+)” rating on shares of ANI Pharmaceuticals in a research report on Monday, June 1st. Finally, Zacks Research downgraded shares of ANI Pharmaceuticals from a “strong-buy” rating to a “hold” rating in a report on Thursday, May 14th. Five investment analysts have rated the stock with a Buy rating and three have assigned a Hold rating to the stock. Based on data from MarketBeat, the company has a consensus rating of “Moderate Buy” and a consensus price target of $107.33.

About ANI Pharmaceuticals

ANI Pharmaceuticals, Inc is a United States–based specialty pharmaceutical company focused on the development, manufacturing and commercialization of generic and branded prescription drugs. The company operates as an end-to-end provider, offering services that range from active pharmaceutical ingredient (API) production and formulation development to finished dosage form manufacturing and packaging.

ANI’s product portfolio encompasses injectable and oral therapies across several therapeutic areas, including endocrinology, oncology, pain management and respiratory care.